



# Supplemental Figure S6

## A



## B



**Supplemental Figure S6. *NXT2* expression is not associated with neuroblastoma disease subtypes**

**A**, OncoPrint of common neuroblastoma alterations in the GMKF tumor dataset of 200 neuroblastoma tumors with copy number, mutation, and expression data. Alterations in *MYCN*, *ALK*, *ATRX*, and *NRAS* are shown. Samples are ordered by *NXT2* expression from highest (left) to lowest (right). **B**) Expression signatures from van Groningen et al. (35) were used to rank 649 tumor samples in the Kocak et al. dataset (34) from highest expression of the adrenergic signature to highest expression of the mesenchymal signature. At the bottom, *MYCN* amplification is shown (grey = amplified, white = non-amplified) and *NXT2* expression is shown.